Changes in BIOCORP’s Governance
23 Dicembre 2019 - 6:00PM
Business Wire
∙ Chairman of the Board and Chief Executive
Officer will be two separate functions
∙ Eric Dessertenne becomes Chief Executive
Officer
∙ Jacques Gardette keeps his mandate as
Chairman of the Board of Directors
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA
PME), a French company specializing in the development and
manufacturing of medical devices and smart drug delivery systems,
announces that the Board of Directors meeting today accepted
Jacques Gardette's decision to resign from his position as Chief
Executive Officer and decided to separate the functions of Chairman
of the Board of Directors and Chief Executive Officer. As a result,
Eric Dessertenne, previously Chief Operating Officer of BIOCORP, is
appointed Chief Executive Officer. Jacques Gardette keeps his
mandate as Chairman of the Board of Directors.
Jacques Gardette, Chairman of the Board of Directors of
BIOCORP and founder, said: "Eric Dessertenne joined BIOCORP in
2014 as Director of Commercial Operations and Business Development
before being appointed COO in December 2016. These five years of
close cooperation with Eric Dessertenne have established absolute
trust between us. Eric Dessertenne has greatly contributed to
BIOCORP's exceptional recognition, notably by successfully
completing our strategic shift in the field of connected
healthcare. This field, which now accounts for more than half of
our business, has been vigorously stimulated by the signing of many
major contracts with international pharmaceutical companies, mainly
over the last six months. I am very pleased that Eric will succeed
me as CEO and have no doubt that he will lead BIOCORP to the level
of international development that its highly qualified teams and
exceptional products deserve".
Eric Dessertenne, Chief Executing Officer of BIOCORP,
commented: " I would like to thank the members of the Board of
Directors, and especially Jacques Gardette, for the trust they have
shown by appointing me as Chief Executive Officer. Today, BIOCORP
has a unique positioning in connected products and solutions. I am
very motivated to continue, in my capacity as Chief Executive
Officer and alongside all of BIOCORP's teams, to pursue and
strengthen the Company's exceptional growth. “
ABOUT BIOCORP Founded in 2004 in Issoire (near
Clermont-Ferrand), France, BIOCORP is a French company specializing
in the development and manufacturing of medical devices and
innovative drug delivery systems. It is listed as ‘Innovative
Company’ by the French public investment bank Bpifrance. With over
twenty years of experience and more than 30 manufactured products,
BIOCORP is a key player in the industry, providing drug delivery
solutions that meet the evolving needs of patients. Today, BIOCORP
continues to innovate in medical plastics, its core business, and
to market traditional devices (alternative to aluminum capsules,
syringe and vial administration systems) that have been an
important source of recurring income. Its solid expertise and
capacity to innovate have allowed the company to develop new
Internet-connected products, including MallyaTM, a smart cap for
pen injectors that captures injection data and automatically
transmits data to a mobile app, helping patients to manage their
treatment. The company has a team of 54 employees. BIOCORP is
listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more
information, please visit www.biocorpsys.com Follow us on Twitter
@BIOCORPSystems
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191223005012/en/
BIOCORP Jacques Gardette Chairman of the Board
investisseurs@biocorp.fr
Éric Dessertenne Chief Executing Officer
Sylvaine Dessard Marketing & Communication Director
rp@biocorp.fr + 33 (0)6 88 69 72 85
ULYSSE COMMUNICATION Bruno ARABIAN
barabian@ulysse-communication.com +33 (0)6 87 88 46 26
Nicolas DANIELS ndaniels@ulysse-communication.com +33 (0)6 63 66
59 22
Grafico Azioni Biocorp (EU:ALCOR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Biocorp (EU:ALCOR)
Storico
Da Apr 2023 a Apr 2024